Eli Lilly and Company Establishes Presence in New York City as a Hub for Biopharmaceutical Research

Eli Lilly and Company has made a significant move by becoming the first tenant of New York City's new Alexandria Center for Science and Technology at East River Science Park, marking a significant investment in the city's biopharmaceutical research sector. This development comes as part of the company's transformation into a fully integrated pharmaceutical network, where it is increasingly collaborating with external organizations to accelerate innovation and bring new treatments to patients. The new location at East River Science Park provides unparalleled access to academic research organizations in the New York area, with nearly 20 current FIPNet partners located in proximity to the new site.

Key Takeaways:

Eli Lilly and Company has become the first tenant of New York City's new Alexandria Center for Science and Technology at East River Science Park, a biotech park located adjacent to the NYU Langone Medical Center in Manhattan.
The biotech park will house ImClone's Research Division, including approximately 125 ImClone scientists, with plans to add more scientists in areas that support expansion of the ImClone pipeline.
The new location enables unprecedented access to academic research organizations in the New York area, with nearly 20 current FIPNet partners in proximity.
ImClone's manufacturing, development, and administrative operations will remain based in New Jersey.
Mayor Bloomberg is a major supporter of the move, citing the need for New York City to capitalize on its scientific assets to create a thriving commercial bioscience industry.
Eli Lilly and Company's transformation into a fully integrated pharmaceutical network involves collaborating with external organizations to speed innovation to patients.
The company has six ImClone molecules in its pipeline, bringing the total number of oncology molecules in clinical development to 23 and the number of unique investigational medicines in the Lilly pipeline to 66.
One of those molecules, IMC-1121B, is in Phase III development for breast cancer and will be evaluated in another Phase III trial for gastric cancer.
The pivotal trial will be conducted at approximately 250 academic research centers across five continents.
The Phase III gastric cancer study aims to evaluate the effect of IMC-1121B on the overall survival of patients with metastatic gastric cancer following disease progression on standard first-line chemotherapeutic regimens.
Gastric cancer is a major cause of mortality and morbidity, with more than 800,000 deaths annually worldwide and over 21,000 diagnoses in the United States alone.

Statistics:

The new Alexandria Center for Science and Technology at East River Science Park will house ImClone's Research Division.
125 ImClone scientists will be based at the new site.
20 current FIPNet partners are located in proximity to the new location.
23 oncology molecules are in clinical development at Eli Lilly and Company.
66 unique investigational medicines are in the Lilly pipeline.
250 academic research centers across five continents will participate in the Phase III gastric cancer trial.
Gastric cancer is diagnosed over 21,000 times annually in the United States alone.
Gastric cancer is the second leading cause of cancer death worldwide, with over 800,000 deaths annually.

Sources:

Biotech Week editors from staff and other reports